# Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

> **NCT04440345** · PHASE1,PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** IBI362
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04440345
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2021-06-16
- **Final completion:** 2021-08-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440345, "Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04440345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*